Section Arrow
ANNX.NASDAQ
- Annexon
Quotes are at least 15-min delayed:2024/05/13 17:49 EDT
Last
 4.87
+0.12 (+2.53%)
Day High 
5.17 
Prev. Close
4.75 
1-M High
6.56 
Volume 
1.34M 
Bid
4.7
Ask
5.09
Day Low
4.795 
Open
4.95 
1-M Low
4.26 
Market Cap 
432.92M 
Currency USD 
P/E -- 
%Yield
10-SMA 4.78 
20-SMA 4.75 
50-SMA 5.53 
52-W High 8.4 
52-W Low 1.57 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.77/-1.06
Enterprise Value
462.11M
Balance Sheet
Book Value Per Share
2.75
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NVAXNovavax13.11+4.23+47.64%-- 
DNAGinkgo Bioworks Holdings0.8407+0.0798+10.49%-- 
ACIUAC Immune SA3.3+0.99+42.86%-- 
JAGXJaguar Health0.290795-0.001305-0.45%-- 
TVGNTevogen Bio Holdings1+0.0155+1.57%-- 
Quotes are at least 15-min delayed:2024/05/13 17:49 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.